Evidence map›Paper›PMID 36803566›Full record

ReviewEuropean journal of medical research2023

Emerging role of mesenchymal stem/stromal cells (MSCs) and MSCs-derived exosomes in bone- and joint-associated musculoskeletal disorders: a new frontier.

Mohammad Hadi Gerami, Roya Khorram, Soheil Rasoolzadegan, Saeid Mardpour, Pooria Nakhaei, Soheyla Hashemi, Bashar Zuhair Talib Al-Naqeeb, Amir Aminian, Sahar Samimi

RetractedAbstract readReviewRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mohammad Hadi GeramiBone and Joint Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Roya KhorramBone and Joint Diseases Research Center, Department of Orthopedic Surgery, Shiraz University of Medical Sciences, Shiraz, Iran.
Soheil RasoolzadeganDepartment of Surgery, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Saeid MardpourDepartment of Radiology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Pooria NakhaeiEndocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Soheyla HashemiObstetrician, Gynaecology & Infertility Department, Isfahan University of Medical Sciences, Isfahan, Iran.
Bashar Zuhair Talib Al-NaqeebAnesthesia Technology Department, Al-Turath University College, Al Mansour, Baghdad, Iraq.
Amir AminianBone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran. amir.aminian1975@gmail.com.
Sahar SamimiTehran University of Medical Sciences, Tehran, Iran. Shrsamimi@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes are membranous vesicles with a 30 to 150 nm diameter secreted by mesenchymal stem/stromal cells (MSCs) and other cells, such as immune cells and cancer cells. Exosomes convey proteins, bioactive lipids, and genetic components to recipient cells, such as microRNAs (miRNAs). Consequently, they have been implicated in regulating intercellular communication mediators under physiological and pathological circumstances. Exosomes therapy as a cell-free approach bypasses many concerns regarding the therapeutic application of stem/stromal cells, including undesirable proliferation, heterogeneity, and immunogenic effects. Indeed, exosomes have become a promising strategy to treat human diseases, particularly bone- and joint-associated musculoskeletal disorders, because of their characteristics, such as potentiated stability in circulation, biocompatibility, low immunogenicity, and toxicity. In this light, a diversity of studies have indicated that inhibiting inflammation, inducing angiogenesis, provoking osteoblast and chondrocyte proliferation and migration, and negative regulation of matrix-degrading enzymes result in bone and cartilage recovery upon administration of MSCs-derived exosomes. Notwithstanding, insufficient quantity of isolated exosomes, lack of reliable potency test, and exosomes heterogeneity hurdle their application in clinics. Herein, we will deliver an outline respecting the advantages of MSCs-derived exosomes-based therapy in common bone- and joint-associated musculoskeletal disorders. Moreover, we will have a glimpse the underlying mechanism behind the MSCs-elicited therapeutic merits in these conditions.

Indexed as

ExosomesJoint DiseasesMesenchymal Stem CellsMicroRNAsMusculoskeletal DiseasesHumansMicroRNAsCartilageExosomesMesenchymal stem/stromal cells (MSCs)Musculoskeletal disorders Bone

Identifiers

PMID36803566
PMCPMC9939872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.